Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

Bristol Myers Squibb (NYSE:BMY) is paying up to $11.1B in a licensing agreement to help develop BioNTech's (NASDAQ:BNTX) immunotherapy bispecific antibody BNT327 for solid tumors. The candidate ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

BioNTech's acquisition of Biotheus includes $800M upfront and up to $150M in milestone payments. The deal grants BioNTech full rights to late-stage bispecific antibody BNT327/PM8002. From tariffs ...

Doctors are exploring whether adding BNT327 to standard chemotherapy will help it to work better. But they don’t know this for sure, so they want to find this out. First, they need to find the best ...

BNT327, BioNTech’ s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

BioNTech and Bristol Myers Squibb announced a collaboration to co-develop the bispecific antibody BNT327 for solid tumors. Quiver AI Summary. BioNTech and Bristol Myers Squibb have announced a ...